Adjuvant Pembrolizumab Indication in RCC
Adjuvant pembrolizumab is strongly indicated for adult patients with clear-cell renal cell carcinoma at intermediate-high or high risk of recurrence following complete surgical resection (nephrectomy with or without metastasectomy), based on proven overall survival benefit. 1
Specific Patient Eligibility Criteria
Based on the KEYNOTE-564 trial definition, pembrolizumab is indicated for patients meeting ANY of the following criteria after complete resection 1, 2:
Intermediate-High Risk (M0 Disease):
- pT2, grade 4 OR sarcomatoid differentiation, N0 M0
- pT3, any grade, N0 M0
High Risk (M0 Disease):
- pT4, any grade, N0 M0
- Any pT stage with N+ (node positive), M0
M1 No Evidence of Disease (NED):
- Complete resection of primary tumor plus soft-tissue metastases within ≤1 year from nephrectomy
Evidence Supporting the Recommendation
The 2025 EAU guidelines upgraded pembrolizumab from a weak to a strong recommendation based on mature overall survival data 1. The KEYNOTE-564 trial demonstrated:
- Overall survival benefit: HR 0.62 (95% CI 0.44-0.87; p=0.005) at 57.2 months median follow-up 3
- 48-month OS: 91.2% with pembrolizumab vs 86.0% with placebo 3
- Disease-free survival: HR 0.72 (95% CI 0.59-0.87) 1
- No deterioration in quality of life 1
This represents a clinically meaningful mortality reduction of 38%, which is the critical outcome that justified the upgrade to a strong recommendation 1.
Treatment Regimen
- Dose: 200 mg intravenously every 3 weeks 2
- Duration: Up to 17 cycles (approximately 1 year) 1, 2
- Timing: Must be initiated within 12 weeks after nephrectomy 4
Critical Safety Considerations
While pembrolizumab improves survival, a significant proportion of patients experience serious adverse events that must be thoroughly discussed 1:
- Grade 3-4 treatment-related adverse events: 18.6% (vs 1.2% with placebo) 3
- Serious adverse events of any cause: 20.7% (vs 11.5% with placebo) 3
- Treatment discontinuation due to adverse events: 19% in real-world data 5
Most common serious toxicities include:
No treatment-related deaths occurred in the pivotal trial 3, 6.
Important Clinical Caveats
Histology Requirement:
Pembrolizumab is only indicated for clear-cell RCC—not for non-clear cell histologies 1, 2.
Biomarker Limitations:
No validated biomarkers exist for patient selection, meaning some patients will be overtreated 1. This reality necessitates frank discussions about the risk-benefit ratio with each patient 7.
Subsequent Therapy Considerations:
If recurrence occurs during or shortly after adjuvant pembrolizumab, do NOT use another PD-1/PD-L1 inhibitor 1. The EAU issues a weak recommendation against ICI rechallenge in this setting. Instead, use VEGFR-targeted therapy (cabozantinib preferred) 8.
Negative Trials Context:
Other adjuvant ICI trials (IMmotion010 with atezolizumab, CheckMate 914 with nivolumab/ipilimumab, PROSPER with perioperative nivolumab) were all negative 1, 7. Pembrolizumab remains the only adjuvant immunotherapy with proven survival benefit in RCC 9.
Regulatory Approval
Pembrolizumab received FDA approval for adjuvant RCC treatment based on these data 2, and the 2025 EAU guidelines now provide the strongest level of recommendation (strong recommendation, Level I evidence) 1.
Shared Decision-Making Algorithm
Given the balance of significant survival benefit against substantial toxicity risk:
- Confirm eligibility: Clear-cell histology + risk criteria from KEYNOTE-564
- Assess performance status: ECOG 0-1 required
- Discuss absolute benefits: ~5% improvement in 48-month OS, delayed recurrence
- Discuss toxicity: ~19% risk of serious adverse events requiring treatment discontinuation
- Consider patient factors: Age <65, N1 disease, and sarcomatoid features predict worse outcomes even with treatment 5
- Document informed consent addressing both benefits and risks
The strong recommendation reflects that for most eligible patients, the mortality benefit outweighs the toxicity risk, but individual circumstances and patient preferences remain paramount 1, 7.